In a subcutaneous Hepa129 mouse HCC model, Belinostat was observed to enhance anti-CTLA-4 antitumor activity by promoting early infiltration of M1 macrophages and suppressing regulatory T cells (169). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.